Idras

Idras is a biotechnology company focused on developing next-generation therapies for autoimmune and inflammatory diseases by targeting Toll-like receptors (TLRs). The company's primary focus is on the development of potent and selective small molecule antagonists of TLR7, TLR8, and TLR9, which play critical roles in the pathogenesis of conditions such as systemic lupus erythematosus and psoriasis. By modulating these innate immune pathways, Idras aims to provide more effective and safer treatment options for patients with chronic inflammatory disorders. The company leverages its deep expertise in TLR biology and medicinal chemistry to advance its pipeline of novel therapeutic candidates toward clinical development.